Last reviewed · How we verify
Atherosclerotic cardiovascular disease
Approved treatments
- Leqvio · Novartis
Leqvio works by binding to PCSK9, preventing it from breaking down LDL receptors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Atherosclerotic cardiovascular disease patent landscape — cliff calendar, originator estates, attackable patents
- Atherosclerotic cardiovascular disease treatment landscape brief
- Atherosclerotic cardiovascular disease treatment updates RSS
Frequently asked questions about Atherosclerotic cardiovascular disease
What drugs treat Atherosclerotic cardiovascular disease?
Tracked treatments include Leqvio.
What is the treatment for Atherosclerotic cardiovascular disease?
Standard treatment for Atherosclerotic cardiovascular disease includes Leqvio. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Atherosclerotic cardiovascular disease patent cliff · Atherosclerotic cardiovascular disease CI report
- Treatment: Leqvio · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing